- Home
- ALXO vs ELMD Comparison
ALXO vs ELMD Comparison
Compare ALXO & ELMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | ELMD |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.8M | 208.1M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ALXO | ELMD |
|---|---|---|
| Price | $1.99 | $38.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $3.50 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 698.5K | 55.8K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.36 | ★ 46.55 |
| EPS | N/A | ★ 0.91 |
| Revenue | N/A | ★ $54,716,000.00 |
| Revenue This Year | N/A | $15.59 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | ★ N/A | $42.36 |
| Revenue Growth | N/A | ★ 13.83 |
| 52 Week Low | $0.41 | $17.73 |
| 52 Week High | $2.66 | $39.25 |
Technical Indicators
Market Signals| Indicator | ALXO | ELMD |
|---|---|---|
| Relative Strength Index (RSI) | 54.37 | 76.39 |
| Support Level | $1.44 | $23.47 |
| Resistance Level | $2.27 | N/A |
| Average True Range (ATR) | 0.14 | 2.37 |
| MACD | 0.01 | 0.99 |
| Stochastic Oscillator | 52.94 | 89.41 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About ELMD Electromed Inc.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.